Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT1001 versus placebo in Fabry disease with AT1001-responsive GLA mutations
NL-OMON34756Phase 3Not yet recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Mar 2010
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of migalastat in Fabry disease (FD) (3 arms), sponsored by Amicus Therapeutics. Primary endpoint: Kidney GL-3 interstitial capillary histology. Planned start Mar 2010; status: not yet recruiting.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON34756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34756.